HC Wainwright started coverage on shares of Milestone Pharmaceuticals (NASDAQ:MIST - Get Free Report) in a research note issued on Thursday, MarketBeat.com reports. The brokerage set a "buy" rating and a $5.00 price target on the stock. HC Wainwright's price objective would indicate a potential upside of 187.36% from the company's current price.
A number of other research firms have also recently issued reports on MIST. TD Securities cut Milestone Pharmaceuticals from a "buy" rating to a "hold" rating in a research note on Tuesday, April 1st. Cowen cut Milestone Pharmaceuticals from a "buy" rating to a "hold" rating in a research note on Tuesday, April 1st. Finally, TD Cowen cut Milestone Pharmaceuticals from a "strong-buy" rating to a "hold" rating in a research note on Tuesday, April 1st. Three research analysts have rated the stock with a hold rating and two have issued a buy rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of "Hold" and a consensus price target of $7.00.
Get Our Latest Analysis on MIST
Milestone Pharmaceuticals Stock Performance
MIST traded up $0.09 during trading hours on Thursday, hitting $1.74. 789,111 shares of the stock were exchanged, compared to its average volume of 916,470. The stock has a 50-day simple moving average of $1.14 and a 200-day simple moving average of $1.69. Milestone Pharmaceuticals has a 12 month low of $0.63 and a 12 month high of $2.75. The stock has a market cap of $93.03 million, a price-to-earnings ratio of -2.15 and a beta of 0.92. The company has a debt-to-equity ratio of 2.18, a current ratio of 15.40 and a quick ratio of 15.40.
Milestone Pharmaceuticals (NASDAQ:MIST - Get Free Report) last posted its earnings results on Wednesday, May 14th. The company reported ($0.31) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.19) by ($0.12). Analysts anticipate that Milestone Pharmaceuticals will post -0.62 earnings per share for the current year.
Institutional Inflows and Outflows
A number of large investors have recently modified their holdings of MIST. Propel Bio Management LLC acquired a new position in shares of Milestone Pharmaceuticals during the first quarter valued at $1,161,000. Toronto Dominion Bank acquired a new position in shares of Milestone Pharmaceuticals during the fourth quarter valued at $1,770,000. Boxer Capital Management LLC acquired a new position in shares of Milestone Pharmaceuticals during the fourth quarter valued at $729,000. Walleye Capital LLC acquired a new position in shares of Milestone Pharmaceuticals during the first quarter valued at $74,000. Finally, Virtu Financial LLC acquired a new position in shares of Milestone Pharmaceuticals during the fourth quarter valued at $170,000. 86.18% of the stock is owned by institutional investors and hedge funds.
About Milestone Pharmaceuticals
(
Get Free Report)
Milestone Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization of cardiovascular medicines. The company's lead product candidate is etripamil, a novel and potent calcium channel blocker, which is in Phase III clinical trial for the treatment of paroxysmal supraventricular tachycardia in the United States and Canada; and Phase II clinical trial for the treatment of atrial fibrillation and rapid ventricular rate.
Read More

Before you consider Milestone Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Milestone Pharmaceuticals wasn't on the list.
While Milestone Pharmaceuticals currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Explore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.